FULC logo

FULC
Fulcrum Therapeutics Inc

2,295
Mkt Cap
$476.43M
Volume
559.00
52W High
$15.74
52W Low
$3.73
PE Ratio
-6.24
FULC Fundamentals
Price
$7.15
Prev Close
$7.44
Open
$7.32
50D MA
$7.98
Beta
1.33
Avg. Volume
1.38M
EPS (Annual)
-$1.18
P/B
1.43
Rev/Employee
$0.00
$370.68
Loading...
Loading...
News
all
press releases
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has i...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) posted its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06...
MarketBeat·2d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics Q1 Earnings Call Highlights
Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase...
MarketBeat·3d ago
News Placeholder
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga·3d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9% - Time to Sell?
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.9% - Here's What Happened...
MarketBeat·10d ago
News Placeholder
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Grows By 41.1%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat·15d ago
News Placeholder
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday...
MarketBeat·18d ago
News Placeholder
Aberdeen Group plc Has $14.18 Million Stock Holdings in Fulcrum Therapeutics, Inc. $FULC
Aberdeen Group plc raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 809.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·22d ago
News Placeholder
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Brokerages
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and sev...
MarketBeat·26d ago
<
1
2
...
>

Latest FULC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.